



## PHEBURANE® PATIENT ENROLLMENT FORM INSTRUCTIONS

The Patient Enrollment Form is required to initiate treatment with Pheburane® (sodium phenylbutyrate) oral pellets.

#### **Healthcare Professionals Instructions:**

- 1. Complete all required patient information.
- **2.** Complete all required insurance information for the patient and attach copies of the front and back of the patient's medical and prescription insurance cards.
- **3.** Complete the diagnosis and prescription information in its entirety; all fields are required. The patient's healthcare provider should fill out this section.
- **4.** Complete all required prescriber information, including the contact information for the practice or facility.
- **5.** A wet signature is required from the patient's healthcare provider.
- **6.** Fax the completed form to either: Accredo Health Group, Inc at **1.888.454.8488**. Questions? Call **1.877.791.1171** CVS Specialty Pharmacy at 1.800.323.2455 Questions? Call **1.866.833.3752**
- **7.** Check with your patient to ensure he or she has printed, signed, and dated the required Patient Authorization Form providing HIPAA authorization for Unik Support Program, in order to initiate patient support located on page 3.

· -		
DIAGNOSIS (REQUIRED)		
Diagnosis including ICD-10 Code:	Ornithine transcarbamylase deficiency/OTC (E72.4)	Carbamylphosphate synthetase/CPS (E72.29)
Citrullinemia/ASSD (E72.23)	Disorder of urea cycle metabolism, unspecified (E72.20)	
Other diagnosis, ICD-10		
PATIENT INFORMATION		
First Name:	Middle Initial: Last Name	:
DOB:/ Gender:	Male Female	
Address:	City:	_ State: ZIP:
Home Phone: ()	Mobile Phone: ( )	Mobile Phone: ()
Email:		
Leave Messages: Yes No	Preferred time to call: AM PM Preferred Langu	lage:
Alternate Contact Name:		Relationship:
Alternate Contact Phone:	Alternate Cont	act Email:
Leave Messages with Alternate Co	ntact: Yes No Preferred time to call: AM	PM Preferred Language:

Please provide copies of front & back of all medical & prescription insurance cards



PHE-2022-0005-04 Page 1 of 3



Prescriber's Signature:



# PHEBURANE® PATIENT ENROLLMENT FORM

Patient Name:		Date of B	irth:					
INSURANCE INFORM	•	-			-	•		5.)
Primary Insurance Company				=				. NA : : -
Phone: ( ) Commercial Other:							•	
Policy #:							Croup #:	
Policyholder Name:								
Relationship:				•				
Prescription Card: Yes								
Identification #:								
Policyholder Name:								
,				•				
PRESCRIBER INFORM						of Contact		one
First and Last Name:								
NPI #:								
Office/Clinic/Institution Address:								
Phone: ( )								
PRESCRIPTION INFO				-	4 g/bottle)			
Patient Weight:			Date Taken:					
Patient Height:		_		No Kno	_	_		
Complete Listing of all Conc							•	
Allergies:								
Take grams by mo Maximum daily dose is 20 g Pheburane® oral pellets as Pour oral pellets directly in formula) OR sprinkle pellet	grams. Measure dose grams (g) of sodium to dosing spoon to m	using only the phenylbutyra neasure the d	he calibrated of te. For oral actors. Patient: s	dosing spoon prov dministration only swallow pellets wit	vided in the . Pheburane th a drink (w	packaging. Dos ® must be take ater, fruit juice	sing spoon mea en with food (me es, or protein-fre	sures eal or snack). ee infant
Instructions:								
PRESCRIBER AUTHOR	RIZATION							
Prescriber Certification: I certify that and their respective employees or againcluding providing logistical and non-I also certify that (1) my patient or his gram and (2) I have obtained the patie to assess insurance coverage for Med to convey this prescription by facsimil Program as a result of this form is for medicine or any other Medunik produ will not seek reimbursement for any rakes no representation or guarante such as e-prescribing, state-specific prenrollment process in the Unik Suppatient will not benefit from the sen Patient Authorization contained with	ents (collectively, "Medunik") we medical treatment support a where personal representative ent's authorization to release unik's medicine and assistance only to the dispensing phare the named patient only and fact or service, for any other predication or service provide the completion and submission completion form, fax language port Program has initiated; vices and support offered by	will use this informing assistance in ir has provided a si, such information ce in initiating or comacy, to the exteries not being made erson; (b) my decied by or through the on of coverage or inmbursement for a e, etc. Noncomplia however, your part the Program unli	nation to administe nitiating or continui gned HIPAA author as may be required continuing Medunik nt permitted under in exchange for an sion to prescribe M ne Program from ar reimbursement-rel ny item or service. ance with state-sper atient must sign a ess your patient si	the Unik Support Progring Medunik's medicine a ization that allows me to the foreacceope of the foreacceope	am (the "Program is prescribed, and is share protected up, Inc. and other d. I appoint the Pi rstand and agree eement or under ased solely on m or third-party ins the responsibility e prescriber is to result in outreach to complete enro tion, consenting	n"), which provides a a deducating about the latest hinformation or entities (or another rogram, on my behalt that (a) any medical standing that I would by professional deterrurer. I understand the of the patient and hecomply with his/her in to the prescriber. Ellment in the Unik Storeceiving such set	wide array of patient e insurance process. with Medunik for pur party acting on beha lf, to proceed with sertion drecommend, prescr mination of medical mat Medunik may mon eathcare provider. M seathcare providers of petition out and sign Support Program. Ple prvices. If your patien	-focused services, By my signature, rposes of the Pro- lif of Medunik) rvices offered and ed through the ibe, or use Medunik's ecessity; and (c) I dify or terminate the Medunik USA, Inc. bition requirements ning this form, the ease note that your
"Dispense As Written" / Br No Substitution / DAW / N	•	sary / Do Not	Substitute /	May Substitute /	Product Se	lection Permit	ted /Substitution	on Permissible

PHE-2022-0005-04 Page 2 of 3

CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution"

Date:

Prescriber's Signature:





### PHEBURANE® PATIENT ENROLLMENT FORM

# Patient Consent for Patient Information, Enrolling in Services, and Accessing Financial Support (referred to as "Patient Authorization")

I hereby authorize my healthcare providers, my health insurance carriers, and my pharmacies to use and disclose my individually identifiable health information, including my medical records, insurance coverage information, and my name, address, and telephone number to Unik Support Program, Inc. and its affiliates and their respective agents and representatives (collectively, "Medunik"), including third parties authorized by Medunik to administer drug support and to dispense drugs (collectively, "Unik Support Program") for the following purposes: (1) to establish eligibility for benefits; (2) to communicate with my healthcare providers and me about my treatment or condition and related products; (3) to facilitate the provision of products, supplies, or services by a third party including, but not limited to, specialty pharmacies; (4) to register me in any applicable product registration program required for my treatment; (5) to enroll me in eligible patient support programs offered by Unik Support Program and/or Medunik, including nursing or patient access support services (government-reimbursed programs may not be eligible for all support services offered; please contact Unik Support Program for determination); and (6) to send me marketing information or offer me products and services related to my treatment or condition (or other products or services in which I might be interested) and to contact me occasionally to obtain my feedback (for market research purposes only) about my treatment, my condition, or my experience with Medunik and/or Unik Support Program otherwise as required or permitted by law. I understand the pharmacies may receive a fee from Medunik in exchange for (1) providing me with certain materials and information described above, and (2) using or disclosing certain health information pursuant to this Authorization. I understand that Medunik as well as my healthcare providers, cannot require me, as a condition of having access to medications, prescription drugs, treatment, or other care, to sign this Authorization.

I understand that I am entitled to a copy of this Authorization.

I understand that information disclosed pursuant to this Authorization in some cases may be redisclosed by the recipient and no longer protected by HIPAA or other privacy laws. But Medunik has agreed to use and disclose my information only for purposes of operating the program. I understand that I may cancel this Authorization at any time by mailing a signed letter requesting such cancellation to Medunik USA, 2 Research Way, Ste 1B, Princeton, NJ 08540. This cancellation will not apply to any information used or disclosed by my healthcare providers and/or health insurance carriers based on this Authorization before they are notified that I have cancelled it. Unless a shorter expiration period is required by state law, this Authorization is valid for whichever is greater: (a) the duration of remaining on this treatment or (b) 10 years from the date signed below. A photocopy of this Authorization will be treated in the same manner as the original.

Date:	Patient's Printed Name:		
Legally Authorized Representati	ve's Printed Name (if required):		
Patient's/Legally Authorized Rep	resentative's Signature:		
Patient's/Legally Authorized Re	presentative's Home Address		
Address:	City:	State: _	ZIP:
Patient's/Legally Authorized Rep	resentative's Telephone: Phone: (	)	Home Mobile
Patient's/Legally Authorized Rep	resentative's Email Address:		
Legally Authorized Representative	e's Relationship to Patient: Spouse	Parent/Legal Guardian	Representative per Power of Attorney
Is there someone else with who	m we may discuss your protected he	alth information? No	Yes
Name:		Relationship	to you:
Name:		Relationship	to you:



pheburane.com

PHE-2022-0005-04 Page 3 of 3